Tarsus präsentiert 11 Abstracts zu Demodex-Blepharitis, okulärer Rosazea und XDEMVY auf Optometrie-Fachkongress

Von Public Technologies12:31 (UTC), 29 September 2026 Aktualisiert

Tarsus Pharmaceuticals Inc. präsentiert 11 wissenschaftliche Abstracts an der American Academy of Optometry 2026 Annual Meeting.
Tagung vom 30. September bis 3. Oktober 2026 in Anaheim, Kalifornien.
Schwerpunkt auf Demodex-Blepharitis, okulärer Rosazea, Real-World-Daten zu XDEMVY (Lotilaner ophthalmic solution) 0.25 Prozent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290830PRIMZONEFULLFEED9835468) on September 29, 2026, and is solely responsible for the information contained therein.